ClinicalTrials.gg
CompletedNCT03335371SimpliciT1Updated Jul 3, 2023Results posted

Evaluation of TTP399 in Patients With Type 1 Diabetes

A Phase 1/2 interventional study of TTP399 and TTP399 in Diabetes Mellitus, Type 1, sponsored by vTv Therapeutics. Completed at 15 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by vTv Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
299th of 1,242
115 · median 40
Started
2017
with 75 others
Phase 1/2
59 of 1,458
8 open now
Registered
807th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 299th largest by enrollment of the 1,242 interventional ones that give a count, is one of 76 that started in 2017, is one of 59 in phase 1/2, and was the 807th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People diagnosed with T1DM, confirmed diagnosis prior to 40 years of age and a diagnosed for minimum of 1 year.
  • Type 1 diabetics using either continuous subcutaneous insulin infusion (with lispro or aspart) or multiple daily doses of insulin
  • Willing to use adequate
  • No major surgeries or significant injuries within the past year and without an active infection.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of T2DM, severely uncontrolled T1DM, maturity-onset diabetes of the young, insulin-requiring T2DM, other unusual or rare forms of diabetes mellitus, diabetes resulting from a secondary disease
  • Receipt of an product within 30 days of the Screening Visit or any therapeutic protein or antibody within 90 days prior to Screening Visit or any previous treatment with TTP399.
  • Living in the same household or related to another participant in this study.
  • Two severe episodes of hypoglycemia that required assistance by a third party within 3 months of Screening Visit
  • Use of antidiabetic medications other than insulin 3 months prior to Screening Visit, systemic 1 month prior to Screening Visit, weight loss medication 2 weeks prior to Screening Visit, and antipsychotic medications 3 months prior to Screening Visit.
  • Participation in any formal weight loss program or contemplating such therapy during the trial.
  • Recent history of use of non-prescribed controlled substances or illicit drugs.
  • Current alcoholism or a history of excessive alcohol consumption within 2 years prior to screening
  • History or presence of symptomatic autonomic neuropathy or chronic gastrointestinal disease.
  • Personal history of long syndrome.
  • Blood donation of approximately 1 pint (500 mL) within 8 weeks before Screening Visit
  • History of hemolytic anemia or chronic transfusion requirement.
  • History of cancer, other than non-melanoma skin cancer or uterine cervical cancer that required therapy in the past 5 years.
  • Breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    TTP399 400 mg

    Drug: TTP399

  • Placebo comparator
    Placebo

    Drug: Placebo Oral Tablet

Interventions

  • DrugTTP399

    Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days

  • DrugTTP399

    Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks

  • DrugPlacebo Oral Tablet

    Phase 2: Participants will receive Placebo oral tablets for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12

    To evaluate the change in glycosylated hemoglobin (HbA1C) in Part 1 and Part 2 participants following multiple-day dosing (at 12 weeks) in subjects with T1MD. Sentinel participants were not evaluated for a change in HbA1C.

    Time frame: Baseline (Day 1) to Week 13

  2. Sentinel - Area Under the Concentration Time Curve (AUC)

    AUC for Day 1 per dose level (400 mg, 800 mg, and 1200 mg) is AUC from 0 to 9 hours.

    Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.

  3. Sentinel - Maximum Drug Concentration (Cmax)

    Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.

  4. Sentinel - Time to Maximum Concentration (Tmax)

    Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.

Secondary outcomes

  1. Percent Change From Baseline Time in Target Glycemic Range (70-180 mg/dL)

    To evaluate the change from baseline time in target range (24 hour)

    Time frame: Baseline (Day 1) to Week 12

  2. Percent Change From Baseline Time in Hypoglycemia (< 54 mg/dL)

    To evaluate the change from baseline time in hypoglycemia (\< 54 mg/dL)

    Time frame: Baseline (Day 1) to Week 12

  3. Percent Change From Baseline Time in Hypoglycemia (< 70 mg/dL)

    To evaluate the change from baseline time in hypoglycemia (\< 70 mg/dL)

    Time frame: Baseline (Day 1) to Week 12

  4. Percent Change From Baseline Time in Hyperglycemia (>180 mg/dL)

    To evaluate the change from baseline time in hypoglycemia (\>180 mg/dL)

    Time frame: Baseline (Day 1) to Week 12

  5. Percent Change From Baseline Time in Hyperglycemia (>250 mg/dL)

    To evaluate the change from baseline time in hypoglycemia (\>250 mg/dL)

    Time frame: Baseline (Day 1) to Week 12

  6. Percent Change From Baseline in Total Daily Insulin Use

    To evaluate the percent change from baseline in total daily insulin use at week 12.

    Time frame: Baseline (Day 1) to Week 12

  7. Change From Baseline in Bolus Insulin Use

    To evaluate the change from baseline in bolus insulin use

    Time frame: Baseline (Day 1) to Week 12

  8. Change From Baseline in Basal Insulin Use

    To evaluate the change from baseline in basal insulin use

    Time frame: Baseline (Day 1) to Week 12

07

Results

Posted Jul 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneSentinelsPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 Placebo
Started59114045
Completed59104043
Not completed00102
Withdrew: Lost to follow-up00001
Withdrew: Withdrawal by subject00001
Withdrew: Randomization error00100

Outcome measures

PrimaryPercent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12

To evaluate the change in glycosylated hemoglobin (HbA1C) in Part 1 and Part 2 participants following multiple-day dosing (at 12 weeks) in subjects with T1MD. Sentinel participants were not evaluated for a change in HbA1C.

Time frame:
Baseline (Day 1) to Week 13
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
percent changePart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 120.08 ± 0.2-0.60 ± 0.20.07 ± 0.06-0.14 ± 0.06
Statistical analysis
  • Part 2 Placebo vs Part 2 TTP399 800 mg · ANCOVA · p = <0.0001 · Mean difference (final values): -0.21 · 95% CI -0.39 to -0.04
PrimarySentinel - Area Under the Concentration Time Curve (AUC)

AUC for Day 1 per dose level (400 mg, 800 mg, and 1200 mg) is AUC from 0 to 9 hours.

Time frame:
Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Reported as:
Mean · ng*h/mL
Sentinel - Area Under the Concentration Time Curve (AUC)
ng*h/mLSentinel 400 mgSentinel 800 mgSentinel 1200 mg
Sentinel - Area Under the Concentration Time Curve (AUC)1778 ± 9921482 ± 3414848 ± 2663
PrimarySentinel - Maximum Drug Concentration (Cmax)
Time frame:
Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Reported as:
Mean · ng/mL
Sentinel - Maximum Drug Concentration (Cmax)
ng/mLSentinel 400 mgSentinel 800 mgSentinel 1200 mg
Sentinel - Maximum Drug Concentration (Cmax)645 ± 219813 ± 1292038 ± 1415
SecondaryPercent Change From Baseline Time in Target Glycemic Range (70-180 mg/dL)

To evaluate the change from baseline time in target range (24 hour)

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline Time in Target Glycemic Range (70-180 mg/dL)
percent changePart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline Time in Target Glycemic Range (70-180 mg/dL)-8 ± 10-3 ± 8-7 ± 14.00.50 ± 16
SecondaryPercent Change From Baseline Time in Hypoglycemia (< 54 mg/dL)

To evaluate the change from baseline time in hypoglycemia (\< 54 mg/dL)

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Median · percent change
Percent Change From Baseline Time in Hypoglycemia (< 54 mg/dL)
percent changePart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline Time in Hypoglycemia (< 54 mg/dL)-0.1 (-2 to 2)-0.1 (-3 to 0)-0.5 (-8 to 8)-0.5 (-8 to 22)
SecondaryPercent Change From Baseline Time in Hypoglycemia (< 70 mg/dL)

To evaluate the change from baseline time in hypoglycemia (\< 70 mg/dL)

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline Time in Hypoglycemia (< 70 mg/dL)
percent changePart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline Time in Hypoglycemia (< 70 mg/dL)-1 ± 3-1 ± 3-2 ± 5-2 ± 8
SecondaryPercent Change From Baseline Time in Hyperglycemia (>180 mg/dL)

To evaluate the change from baseline time in hypoglycemia (\>180 mg/dL)

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline Time in Hyperglycemia (>180 mg/dL)
percent changePart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline Time in Hyperglycemia (>180 mg/dL)9 ± 125 ± 810 ± 171 ± 18
SecondaryPercent Change From Baseline Time in Hyperglycemia (>250 mg/dL)

To evaluate the change from baseline time in hypoglycemia (\>250 mg/dL)

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline Time in Hyperglycemia (>250 mg/dL)
percent changePart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline Time in Hyperglycemia (>250 mg/dL)6 ± 112 ± 12
SecondaryPercent Change From Baseline in Total Daily Insulin Use

To evaluate the percent change from baseline in total daily insulin use at week 12.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Total Daily Insulin Use
percent changePart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Percent Change From Baseline in Total Daily Insulin Use-0.1 ± 8.7-1.7 ± 14.7-1.6 ± 16-7.6 ± 10.1
SecondaryChange From Baseline in Bolus Insulin Use

To evaluate the change from baseline in bolus insulin use

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · units/kg/day
Change From Baseline in Bolus Insulin Use
units/kg/dayPart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Change From Baseline in Bolus Insulin Use-5.9 ± 17.5-1 ± 31.8-3.9 ± 28.4-8.4 ± 22.7
SecondaryChange From Baseline in Basal Insulin Use

To evaluate the change from baseline in basal insulin use

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · units/kg/day
Change From Baseline in Basal Insulin Use
units/kg/dayPart 1 PlaceboPart 1 TTP399 800 mgPart 2 PlaceboPart 2 TTP399 800 mg
Change From Baseline in Basal Insulin Use4.4 ± 7.7-2.3 ± 10.3-0.5 ± 11.6-5.4 ± 7.1
PrimarySentinel - Time to Maximum Concentration (Tmax)
Time frame:
Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Reported as:
Median · hour
Sentinel - Time to Maximum Concentration (Tmax)
hourSentinel 400 mgSentinel 800 mgSentinel 1200 mg
Sentinel - Time to Maximum Concentration (Tmax)1.5 (1.5 to 2.5)1.5 (1.5 to 2.0)2.5 (1.5 to 3.0)

Adverse events

Collected over Treatment-emergent adverse events were those reported at baseline up to 12 weeks (±3) days after the last dose. Unresolved AEs were followed up by the investigator for as long as medically indicated. Sentinel group reported at baseline up to 28 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sentinel 400 mg0/5 (0%)0/5 (0%)2/5 (40%)
Sentinel 800 mg0/5 (0%)0/5 (0%)1/5 (20%)
Sentinel 1200 mg0/5 (0%)0/5 (0%)2/5 (40%)
Placebo (Part 1 and Part 2)0/56 (0%)1/56 (1.8%)32/56 (57.1%)
TTP399 800 mg (Part 1 and Part 2)0/49 (0%)1/49 (2%)25/49 (51%)
Most frequent serious events
Most frequent serious events
EventSentinel 400 mgSentinel 800 mgSentinel 1200 mgPlacebo (Part 1 and Part 2)TTP399 800 mg (Part 1 and Part 2)
Non-Cardiac Chest PainGeneral disorders0/50/50/50/561/49
Coronary Artery DiseaseCardiac disorders0/50/50/51/560/49
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSentinel 400 mgSentinel 800 mgSentinel 1200 mgPlacebo (Part 1 and Part 2)TTP399 800 mg (Part 1 and Part 2)
HypoglycemiaMetabolism and nutrition disorders2/50/50/59/565/49
NauseaGastrointestinal disorders0/50/51/54/563/49
HypocalcemiaMetabolism and nutrition disorders0/51/50/50/560/49
Right Eye DiscomfortEye disorders0/50/51/50/560/49
HeadacheNervous system disorders1/50/50/52/560/49
Upper respiratory tract infectionInfections and infestations0/50/50/56/567/49
Urinary tract infectionInfections and infestations0/50/50/54/560/49
NasopharyngitisInfections and infestations0/50/50/53/563/49
Ear infectionInfections and infestations0/50/50/50/563/49
CoughRespiratory, thoracic and mediastinal disorders0/50/50/53/562/49

Baseline characteristics

Sentinel participants were the same participants throughout the dose levels. Part 1 is the full analysis set. Part 2 is all randomized subjects who received at least 1 dose of the investigational product.

Age, Continuous
Age, Continuous(years)SentinelPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 PlaceboTotal
Mean32 ± 7.438 ± 15.7147 ± 10.1043 ± 15.2642 ± 13.2642.5 ± 13.76
Sex: Female, Male
Sex: Female, Male(Participants)SentinelPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 PlaceboTotal
Female358152556
Male233252053
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SentinelPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 PlaceboTotal
Hispanic or Latino000123
Not Hispanic or Latino58113943106
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SentinelPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 PlaceboTotal
American Indian or Alaska Native000000
Asian000213
Native Hawaiian or Other Pacific Islander000000
Black or African American010012
White57113843104
More than one race000000
Unknown or Not Reported000000
BMI
BMI(kg/m2)SentinelPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 PlaceboTotal
Mean24 ± 328 ± 3.3029 ± 4.1328 ± 4.1628 ± 3.7628 ± 3.8
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(Percent HbA1c in blood)SentinelPart 1 TTP399 800 mgPart 1 PlaceboPart 2 TTP399 800 mgPart 2 PlaceboTotal
Mean6.9 ± 0.77.20 ± 0.427.36 ± 0.417.66 ± 0.567.52 ± 0.597.45 ± 0.7
08

Study locations

15 sites
  • USC Westside Center for Diabetes
    Beverly Hills, California 90211, United States
  • AMCR Institute
    Escondido, California 92025, United States
  • University of Colorado Barbara Davis Center
    Aurora, Colorado 80045, United States
  • Atlanta Diabetes Associate
    Atlanta, Georgia 30318, United States
  • Rocky Mountain Diabetes Center
    Idaho Falls, Idaho 83404, United States
  • Iowa Diabetes Research
    West Des Moines, Iowa 50265, United States
  • Mountain Diabetes and Endocrine Center
    Asheville, North Carolina 28803, United States
  • UNC Diabetes Care Center
    Chapel Hill, North Carolina 27517, United States
  • Duke University Diabetes Research Clinic
    Durham, North Carolina 27710, United States
  • Diabetes & Endocrinology Consultants
    Morehead City, North Carolina 28557, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Wake Forest
    Winston-Salem, North Carolina 27104, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • University of Washington Medicine Diabetes Institute
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C; SimpliciT1 research group. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi: 10.2337/dc20-2684. Epub 2021 Feb 23. PubMed 33622669 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2019, 25 months.

Results were first posted in Jul 2023, 3 years 6 months after primary completion. A results delay was requested in Nov 2020.

Of 44 phase 1/2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 93. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Nov 7, 2017
StartActual
Oct 25, 2017
Primary completionActual
Dec 20, 2019
CompletionActual
Jan 6, 2020
Results delay requested
Nov 24, 2020
Results first posted
Jul 3, 2023
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03335371
Lead sponsor
vTv Therapeutics
Collaborators
Juvenile Diabetes Research Foundation
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Oct 25, 2017
Primary completion
Dec 20, 2019
Completion
Jan 6, 2020
Results posted
Jul 3, 2023
Last update
Jul 3, 2023

Study contacts

Carmen Valcarce, Ph.D.
study director · vTv Therapeutics, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTP399

Start the discussion